View ValuationMedCap 향후 성장Future 기준 점검 3/6MedCap (는) 각각 연간 14.9% 및 6.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 14.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 16.1% 로 예상됩니다.핵심 정보14.9%이익 성장률14.77%EPS 성장률Life Sciences 이익 성장19.9%매출 성장률6.6%향후 자기자본이익률16.10%애널리스트 커버리지Low마지막 업데이트29 Apr 2026최근 향후 성장 업데이트Price Target Changed • Apr 29Price target increased by 9.1% to kr575Up from kr527, the current price target is an average from 2 analysts. New target price is 20% above last closing price of kr478. Stock is up 9.9% over the past year. The company is forecast to post earnings per share of kr19.24 for next year compared to kr14.67 last year.모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 16%After last week's 16% share price gain to kr529, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 28x in the Life Sciences industry in Sweden. Total returns to shareholders of 78% over the past three years.Reported Earnings • May 05First quarter 2026 earnings released: EPS: kr3.72 (vs kr3.37 in 1Q 2025)First quarter 2026 results: EPS: kr3.72 (up from kr3.37 in 1Q 2025). Revenue: kr564.5m (up 14% from 1Q 2025). Net income: kr55.9m (up 11% from 1Q 2025). Profit margin: 9.9% (in line with 1Q 2025). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 17% per year.Buy Or Sell Opportunity • May 04Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.6% to kr458. The fair value is estimated to be kr598, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 15%.Price Target Changed • Apr 29Price target increased by 9.1% to kr575Up from kr527, the current price target is an average from 2 analysts. New target price is 20% above last closing price of kr478. Stock is up 9.9% over the past year. The company is forecast to post earnings per share of kr19.24 for next year compared to kr14.67 last year.New Risk • Apr 10New major risk - Revenue sizeThe company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risk Large one-off items impacting financial results.공시 • Mar 31MedCap AB (publ), Annual General Meeting, May 04, 2026MedCap AB (publ), Annual General Meeting, May 04, 2026, at 16:00 W. Europe Standard Time. Location: at iva, grev turegatan 16 in stockholm, stockholm SwedenRecent Insider Transactions • Feb 13Head of Business Area Specialty Pharma recently bought kr780k worth of stockOn the 9th of February, Anders Larnholt bought around 2k shares on-market at roughly kr520 per share. This transaction amounted to 60% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold kr25m more in shares than they bought in the last 12 months.Reported Earnings • Feb 10Full year 2025 earnings released: EPS: kr14.67 (vs kr14.00 in FY 2024)Full year 2025 results: EPS: kr14.67 (up from kr14.00 in FY 2024). Revenue: kr2.13b (up 18% from FY 2024). Net income: kr219.8m (up 6.0% from FY 2024). Profit margin: 10% (down from 12% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.공시 • Feb 06MedCap AB (publ) to Report Fiscal Year 2026 Results on Feb 05, 2027MedCap AB (publ) announced that they will report fiscal year 2026 results on Feb 05, 2027Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. Independent Director Otto Ankarcrona was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.분석 기사 • Jan 30Estimating The Fair Value Of MedCap AB (publ) (STO:MCAP)Key Insights Using the 2 Stage Free Cash Flow to Equity, MedCap fair value estimate is kr577 Current share price of...Recent Insider Transactions • Dec 08Chairman recently sold kr3.4m worth of stockOn the 5th of December, Karl Tobieson sold around 6k shares on-market at roughly kr537 per share. This transaction amounted to 4.6% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Karl has been a net seller over the last 12 months, reducing personal holdings by kr26m.분석 기사 • Nov 06Earnings Troubles May Signal Larger Issues for MedCap (STO:MCAP) ShareholdersMedCap AB (publ)'s ( STO:MCAP ) stock showed strength, with investors undeterred by its weak earnings report...Reported Earnings • Oct 26Third quarter 2025 earnings released: EPS: kr3.42 (vs kr3.57 in 3Q 2024)Third quarter 2025 results: EPS: kr3.42 (down from kr3.57 in 3Q 2024). Revenue: kr504.8m (up 22% from 3Q 2024). Net income: kr51.2m (down 3.2% from 3Q 2024). Profit margin: 10% (down from 13% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.공시 • Oct 25MedCap AB (publ) to Report Q3, 2026 Results on Oct 23, 2026MedCap AB (publ) announced that they will report Q3, 2026 results on Oct 23, 2026분석 기사 • Sep 25Is MedCap (STO:MCAP) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Aug 28A Look At The Intrinsic Value Of MedCap AB (publ) (STO:MCAP)Key Insights The projected fair value for MedCap is kr683 based on 2 Stage Free Cash Flow to Equity MedCap's kr621...Reported Earnings • Jul 24Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: kr524.1m (up 14% from 2Q 2024). Net income: kr53.7m (down 5.5% from 2Q 2024). Profit margin: 10% (down from 12% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.공시 • Jul 24+ 2 more updatesMedCap AB (publ) to Report Q1, 2026 Results on Apr 29, 2026MedCap AB (publ) announced that they will report Q1, 2026 results on Apr 29, 2026Valuation Update With 7 Day Price Move • Jul 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to kr616, the stock trades at a trailing P/E ratio of 45.9x. Average forward P/E is 24x in the Life Sciences industry in Sweden. Total returns to shareholders of 199% over the past three years.분석 기사 • Jul 13MedCap AB (publ)'s (STO:MCAP) Shares Climb 27% But Its Business Is Yet to Catch UpMedCap AB (publ) ( STO:MCAP ) shares have continued their recent momentum with a 27% gain in the last month alone. The...공시 • Jun 25MedCap AB (publ) (OM:MCAP) acquired XGX PharmaMedCap AB (publ) (OM:MCAP) agreed to acquire XGX Pharma on June 25, 2025. MedCap AB (publ) (OM:MCAP) completed acquisition of XGX Pharma on June 25, 2025.Recent Insider Transactions • May 15Chairman recently sold kr22m worth of stockOn the 12th of May, Karl Tobieson sold around 50k shares on-market at roughly kr444 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Karl's only on-market trade for the last 12 months.공시 • May 10MedCap AB (publ) (OM:MCAP) announces an Equity Buyback for SEK 26 million worth of its shares.MedCap AB (publ) (OM:MCAP) announces a share repurchase program. Under the program, the company will repurchase up to SEK 26 million worth of its shares. The shares shall be acquired at a price per share within the price range applicable on Nasdaq Stockholm at any time, which refers to the interval between the highest bid price and the lowest ask price published continuously by Nasdaq Stockholm. The purpose of the program is to secure the Company's commitment to share-based incentive programs (LTIP 2025/2028) through holdings of unvested shares and to continuously adapt the Company's capital structure to the Company's capital needs and thereby contribute to increased shareholder value, and to enable future acquisitions of companies or businesses to be made through payment with own shares. The program will be valid till August 29, 2025. As of May 7, 2025, the company had 14,981,353 outstanding shares and 0 treasury shares.분석 기사 • May 07MedCap (STO:MCAP) Strong Profits May Be Masking Some Underlying IssuesMedCap AB (publ) ( STO:MCAP ) just released a solid earnings report, and the stock displayed some strength. Despite...분석 기사 • May 04Subdued Growth No Barrier To MedCap AB (publ) (STO:MCAP) With Shares Advancing 28%MedCap AB (publ) ( STO:MCAP ) shareholders would be excited to see that the share price has had a great month, posting...Reported Earnings • Apr 30First quarter 2025 earnings released: EPS: kr3.37 (vs kr3.78 in 1Q 2024)First quarter 2025 results: EPS: kr3.37 (down from kr3.78 in 1Q 2024). Revenue: kr498.3m (up 7.9% from 1Q 2024). Net income: kr50.5m (down 9.8% from 1Q 2024). Profit margin: 10% (down from 12% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • Apr 29Why We Think The CEO Of MedCap AB (publ) (STO:MCAP) May Soon See A Pay RiseKey Insights MedCap to hold its Annual General Meeting on 5th of May Total pay for CEO Anders Dahlberg includes kr3.03m...Buy Or Sell Opportunity • Apr 19Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.2% to kr386. The fair value is estimated to be kr482, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 30%.공시 • Apr 03MedCap AB (publ), Annual General Meeting, May 05, 2025MedCap AB (publ), Annual General Meeting, May 05, 2025, at 16:00 W. Europe Standard Time. Location: iva, grev turegatan 16, stockholm SwedenBuy Or Sell Opportunity • Feb 19Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 27% to kr395. The fair value is estimated to be kr499, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 30%.Recent Insider Transactions • Feb 14Chief Executive Officer recently bought kr3.9m worth of stockOn the 12th of February, Anders Dahlberg bought around 10k shares on-market at roughly kr391 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Anders has been a buyer over the last 12 months, purchasing a net total of kr4.2m worth in shares.분석 기사 • Feb 03Some MedCap AB (publ) (STO:MCAP) Shareholders Look For Exit As Shares Take 34% PoundingMedCap AB (publ) ( STO:MCAP ) shareholders that were waiting for something to happen have been dealt a blow with a 34...공시 • Feb 02MedCap AB (publ) to Report Q3, 2025 Results on Oct 24, 2025MedCap AB (publ) announced that they will report Q3, 2025 results on Oct 24, 2025Reported Earnings • Feb 01Full year 2024 earnings: EPS in line with expectations, revenues disappointFull year 2024 results: EPS: kr14.00 (up from kr11.63 in FY 2023). Revenue: kr1.84b (up 15% from FY 2023). Net income: kr207.4m (up 20% from FY 2023). Profit margin: 11% (in line with FY 2023). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Jan 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 5.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Buy Or Sell Opportunity • Jan 17Now 33% undervalued after recent price dropOver the last 90 days, the stock has fallen 24% to kr411. The fair value is estimated to be kr609, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 34%. Revenue is forecast to grow by 23% in 2 years. Earnings are forecast to grow by 22% in the next 2 years.Buy Or Sell Opportunity • Jan 02Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to kr615. The fair value is estimated to be kr501, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 34%.Buy Or Sell Opportunity • Dec 16Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 22% to kr601. The fair value is estimated to be kr500, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 34%.Recent Insider Transactions Derivative • Dec 09Chief Executive Officer exercised options and sold kr11m worth of stockOn the 4th of December, Anders Dahlberg exercised 45.00k options at around kr217, then sold 35k of the shares acquired at an average of kr544 per share and kept the remainder. For the year to December 2021, Anders' total compensation was 45% salary and 55% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since December 2023, Anders' direct individual holding has increased from 19.46k shares to 20.00k. Company insiders have collectively sold kr19m more than they bought, via options and on-market transactions in the last 12 months.분석 기사 • Nov 16We Think MedCap (STO:MCAP) Can Manage Its Debt With EaseLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: kr3.57 (vs kr2.59 in 3Q 2023)Third quarter 2024 results: EPS: kr3.57 (up from kr2.59 in 3Q 2023). Revenue: kr426.0m (up 17% from 3Q 2023). Net income: kr52.9m (up 38% from 3Q 2023). Profit margin: 12% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year whereas the company’s share price has increased by 39% per year.분석 기사 • Oct 18MedCap AB (publ)'s (STO:MCAP) Earnings Haven't Escaped The Attention Of InvestorsWith a price-to-earnings (or "P/E") ratio of 36x MedCap AB (publ) ( STO:MCAP ) may be sending very bearish signals at...Recent Insider Transactions • Sep 23Chief Executive Officer recently bought kr265k worth of stockOn the 20th of September, Anders Dahlberg bought around 541 shares on-market at roughly kr491 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Anders' only on-market trade for the last 12 months.Reported Earnings • Jul 25Second quarter 2024 earnings released: EPS: kr3.84 (vs kr3.16 in 2Q 2023)Second quarter 2024 results: EPS: kr3.84 (up from kr3.16 in 2Q 2023). Revenue: kr469.9m (up 22% from 2Q 2023). Net income: kr56.8m (up 21% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Over the last 3 years on average, earnings per share has increased by 35% per year whereas the company’s share price has increased by 38% per year.공시 • Jul 25MedCap AB (publ) to Report Q2, 2025 Results on Jul 23, 2025MedCap AB (publ) announced that they will report Q2, 2025 results on Jul 23, 2025Buy Or Sell Opportunity • Jul 01Now 17% undervaluedOver the last 90 days, the stock has risen 40% to kr523. The fair value is estimated to be kr631, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.Buy Or Sell Opportunity • Jun 25Now 21% undervaluedOver the last 90 days, the stock has risen 32% to kr500. The fair value is estimated to be kr629, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.분석 기사 • Jun 06Estimating The Intrinsic Value Of MedCap AB (publ) (STO:MCAP)Key Insights The projected fair value for MedCap is kr631 based on 2 Stage Free Cash Flow to Equity Current share price...분석 기사 • May 21MedCap AB (publ) (STO:MCAP) Stocks Shoot Up 33% But Its P/E Still Looks ReasonableThe MedCap AB (publ) ( STO:MCAP ) share price has done very well over the last month, posting an excellent gain of 33...Buy Or Sell Opportunity • May 13Now 21% undervaluedOver the last 90 days, the stock has risen 26% to kr494. The fair value is estimated to be kr626, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.공시 • May 12MedCap AB (publ) to Report Q1, 2025 Results on Apr 29, 2025MedCap AB (publ) announced that they will report Q1, 2025 results on Apr 29, 2025분석 기사 • May 04Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Reported Earnings • May 04First quarter 2024 earnings released: EPS: kr3.78 (vs kr1.68 in 1Q 2023)First quarter 2024 results: EPS: kr3.78 (up from kr1.68 in 1Q 2023). Revenue: kr463.1m (up 22% from 1Q 2023). Net income: kr56.0m (up 126% from 1Q 2023). Profit margin: 12% (up from 6.5% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.공시 • Apr 03MedCap AB (publ), Annual General Meeting, May 06, 2024MedCap AB (publ), Annual General Meeting, May 06, 2024.공시 • Mar 29MedCap AB (publ) to Report Fiscal Year 2024 Results on Jan 31, 2025MedCap AB (publ) announced that they will report fiscal year 2024 results on Jan 31, 2025분석 기사 • Feb 15MedCap AB (publ)'s (STO:MCAP) P/E Is Still On The Mark Following 25% Share Price BounceDespite an already strong run, MedCap AB (publ) ( STO:MCAP ) shares have been powering on, with a gain of 25% in the...Reported Earnings • Feb 02Full year 2023 earnings released: EPS: kr11.63 (vs kr7.94 in FY 2022)Full year 2023 results: EPS: kr11.63 (up from kr7.94 in FY 2022). Revenue: kr1.60b (up 43% from FY 2022). Net income: kr172.2m (up 46% from FY 2022). Profit margin: 11% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improves as stock rises 19%After last week's 19% share price gain to kr380, the stock trades at a trailing P/E ratio of 37.4x. Average trailing P/E is 49x in the Life Sciences industry in Sweden. Total returns to shareholders of 88% over the past three years.분석 기사 • Dec 21Is Now The Time To Put MedCap (STO:MCAP) On Your Watchlist?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...공시 • Oct 29MedCap AB (publ) to Report Q3, 2024 Results on Oct 25, 2024MedCap AB (publ) announced that they will report Q3, 2024 results on Oct 25, 2024Reported Earnings • Oct 29Third quarter 2023 earnings released: EPS: kr2.59 (vs kr2.47 in 3Q 2022)Third quarter 2023 results: EPS: kr2.59 (up from kr2.47 in 3Q 2022). Revenue: kr368.2m (up 52% from 3Q 2022). Net income: kr38.3m (up 4.6% from 3Q 2022). Profit margin: 10% (down from 15% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.공시 • Jul 31MedCap AB (publ) to Report First Half, 2024 Results on Jul 19, 2024MedCap AB (publ) announced that they will report first half, 2024 results on Jul 19, 2024Reported Earnings • Jul 29Second quarter 2023 earnings released: EPS: kr3.16 (vs kr1.42 in 2Q 2022)Second quarter 2023 results: EPS: kr3.16 (up from kr1.42 in 2Q 2022). Revenue: kr390.0m (up 37% from 2Q 2022). Net income: kr46.8m (up 123% from 2Q 2022). Profit margin: 12% (up from 7.4% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year whereas the company’s share price has increased by 27% per year.공시 • Jul 25MedCap AB (publ) (OM:MCAP) signed an agreement to acquire SurgiCube International B.V. for €8 million.MedCap AB (publ) (OM:MCAP) signed an agreement to acquire Surgicube International B.V. for €8 million on July 24, 2023. Under the transaction, MedCap pays €6 million and adjustments for net debt / cash at closing and an earn-out up to €2 million based on the gross profit growth until December 2024. SurgiCube’s sales in the last 12 months amounted to approximately €3.7 million with almost 24% EBITDA-margin. Key individuals in the business have committed to remain as minority owners, and the former majority owner Ger Vijfvinkel has committed to remain as managing director and then as advisor during a transition phase.분석 기사 • May 06Do MedCap's (STO:MCAP) Earnings Warrant Your Attention?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...공시 • May 05MedCap AB (publ) to Report Q1, 2024 Results on May 03, 2024MedCap AB (publ) announced that they will report Q1, 2024 results on May 03, 2024Reported Earnings • May 03First quarter 2023 earnings released: EPS: kr1.68 (vs kr1.32 in 1Q 2022)First quarter 2023 results: EPS: kr1.68 (up from kr1.32 in 1Q 2022). Revenue: kr384.0m (up 46% from 1Q 2022). Net income: kr24.8m (up 27% from 1Q 2022). Profit margin: 6.5% (down from 7.5% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.Reported Earnings • Feb 12Full year 2022 earnings released: EPS: kr7.94 (vs kr6.52 in FY 2021)Full year 2022 results: EPS: kr7.94 (up from kr6.52 in FY 2021). Revenue: kr1.15b (up 24% from FY 2021). Net income: kr117.6m (up 22% from FY 2021). Profit margin: 10% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.분석 기사 • Nov 23These 4 Measures Indicate That MedCap (STO:MCAP) Is Using Debt SafelyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Anders Hansen is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 30Third quarter 2022 earnings released: EPS: kr2.47 (vs kr1.73 in 3Q 2021)Third quarter 2022 results: EPS: kr2.47 (up from kr1.73 in 3Q 2021). Revenue: kr264.0m (up 31% from 3Q 2021). Net income: kr36.6m (up 43% from 3Q 2021). Profit margin: 14% (up from 13% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.분석 기사 • Sep 21We Ran A Stock Scan For Earnings Growth And MedCap (STO:MCAP) Passed With EaseFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Buying Opportunity • Sep 13Now 21% undervaluedOver the last 90 days, the stock is up 17%. The fair value is estimated to be kr267, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 28%.Buying Opportunity • Aug 02Now 21% undervaluedOver the last 90 days, the stock is up 36%. The fair value is estimated to be kr273, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 28%.공시 • Jul 31MedCap AB (publ) to Report Q2, 2023 Results on Jul 28, 2023MedCap AB (publ) announced that they will report Q2, 2023 results on Jul 28, 2023Board Change • Jul 30High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Anders Hansen is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • Jun 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Anders Hansen is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공시 • May 12+ 1 more updateMedCap AB (publ) to Report Q1, 2023 Results on May 03, 2023MedCap AB (publ) announced that they will report Q1, 2023 results on May 03, 2023Reported Earnings • May 06First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2022 results: EPS: kr1.32 (up from kr0.99 in 1Q 2021). Revenue: kr265.8m (up 19% from 1Q 2021). Net income: kr19.6m (up 34% from 1Q 2021). Profit margin: 7.4% (up from 6.6% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.3%. Earnings per share (EPS) exceeded analyst estimates by 13%. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.분석 기사 • Apr 29Does MedCap (STO:MCAP) Deserve A Spot On Your Watchlist?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...공시 • Mar 29MedCap AB (publ) to Report Q4, 2022 Results on Feb 10, 2023MedCap AB (publ) announced that they will report Q4, 2022 results on Feb 10, 2023Reported Earnings • Feb 11Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: kr6.52 (up from kr4.36 in FY 2020). Revenue: kr939.6m (up 15% from FY 2020). Net income: kr96.5m (up 54% from FY 2020). Profit margin: 10% (up from 7.6% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.3%. Earnings per share (EPS) exceeded analyst estimates by 13%. Over the last 3 years on average, earnings per share has increased by 29% per year and the company’s share price has also increased by 29% per year.분석 기사 • Feb 01MedCap (STO:MCAP) Seems To Use Debt Rather SparinglyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Valuation Update With 7 Day Price Move • Jan 31Investor sentiment improved over the past weekAfter last week's 18% share price gain to kr162, the stock trades at a trailing P/E ratio of 31.3x. Average trailing P/E is 51x in the Life Sciences industry in Sweden. Total returns to shareholders of 94% over the past three years.Buying Opportunity • Jan 21Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 24%. The fair value is estimated to be kr184, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.4% per annum over the last 3 years. Earnings per share has grown by 32% per annum over the last 3 years.Board Change • Jan 02High number of new directorsChairman Karl Tobieson was the last director to join the board, commencing their role in 2021.Recent Insider Transactions • Dec 30Chief Executive Officer recently bought kr348k worth of stockOn the 27th of December, Anders Dahlberg bought around 2k shares on-market at roughly kr174 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr828k. Anders has been a buyer over the last 12 months, purchasing a net total of kr1.1m worth in shares.Recent Insider Transactions • Dec 15Investment Manager recently bought kr828k worth of stockOn the 13th of December, Lars Ångman bought around 5k shares on-market at roughly kr166 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.9m more in shares than they have sold in the last 12 months.Reported Earnings • Oct 30Third quarter 2021 earnings released: EPS kr1.73 (vs kr0.89 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr216.0m (up 23% from 3Q 2020). Net income: kr25.6m (up 95% from 3Q 2020). Profit margin: 12% (up from 7.5% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year whereas the company’s share price has increased by 34% per year.분석 기사 • Aug 03Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Reported Earnings • Jul 31Second quarter 2021 earnings released: EPS kr1.06 (vs kr1.33 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: kr237.1m (up 13% from 2Q 2020). Net income: kr15.7m (down 18% from 2Q 2020). Profit margin: 6.6% (down from 9.1% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.분석 기사 • May 27Does MedCap (STO:MCAP) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Valuation Update With 7 Day Price Move • May 12Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to kr206, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 40x in the Life Sciences industry in Europe. Total returns to shareholders of 170% over the past three years.Recent Insider Transactions • May 09Independent Chairman of the Board recently bought kr1.1m worth of stockOn the 7th of May, Peter von Ehrenheim bought around 5k shares on-market at roughly kr220 per share. This was the largest purchase by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months.분석 기사 • Apr 07Here's Why I Think MedCap (STO:MCAP) Is An Interesting StockSome have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...이익 및 매출 성장 예측OM:MCAP - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20282,615343364441112/31/20272,463308335409112/31/20262,30826629036213/31/20262,176225275339N/A12/31/20252,110220281343N/A9/30/20251,996197258318N/A6/30/20251,908199267326N/A3/31/20251,844202261323N/A12/31/20241,807207294360N/A9/30/20241,791228251308N/A6/30/20241,742214244299N/A3/31/20241,671203219268N/A12/31/20231,589172189228N/A9/30/20231,46615077114N/A6/30/20231,3431496197N/A3/31/20231,2411234782N/A12/31/20221,1241184186N/A9/30/20221,056118100167N/A6/30/20221,01710778146N/A3/31/202296710285156N/A12/31/20219269755116N/A9/30/20218967677109N/A6/30/2021869646090N/A3/31/20218456779104N/A12/31/20208286391115N/A9/30/2020802556488N/A6/30/20207865375101N/A3/31/2020763473862N/A12/31/201975755N/A71N/A9/30/201973443N/A87N/A6/30/201974041N/A107N/A3/31/201972732N/A103N/A12/31/201870924N/A91N/A9/30/201871614N/A57N/A6/30/20186898N/A27N/A3/31/201866010N/A46N/A12/31/20176177N/A41N/A10/31/201777911N/A79N/A7/31/20178023N/A85N/A4/30/20178530N/A81N/A1/31/20179015N/A32N/A10/31/201689710N/A-18N/A7/31/201687419N/A-44N/A4/30/201681820N/A-15N/A1/31/201681718N/A-60N/A10/31/201581817N/A-28N/A7/31/20158258N/A14N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: MCAP 의 연간 예상 수익 증가율(14.9%)이 saving rate(2%)보다 높습니다.수익 vs 시장: MCAP 의 연간 수익(14.9%)이 Swedish 시장(8.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: MCAP 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: MCAP 의 수익(연간 6.6%)이 Swedish 시장(연간 0.04%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: MCAP 의 수익(연간 6.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: MCAP의 자본 수익률은 3년 후 16.1%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 11:14종가2026/05/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스MedCap AB (publ)는 5명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullABG Sundal CollierBjorn RydellABG Sundal Collier SponsoredHans MählerNordea Markets2명의 분석가 더 보기
Price Target Changed • Apr 29Price target increased by 9.1% to kr575Up from kr527, the current price target is an average from 2 analysts. New target price is 20% above last closing price of kr478. Stock is up 9.9% over the past year. The company is forecast to post earnings per share of kr19.24 for next year compared to kr14.67 last year.
Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 16%After last week's 16% share price gain to kr529, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 28x in the Life Sciences industry in Sweden. Total returns to shareholders of 78% over the past three years.
Reported Earnings • May 05First quarter 2026 earnings released: EPS: kr3.72 (vs kr3.37 in 1Q 2025)First quarter 2026 results: EPS: kr3.72 (up from kr3.37 in 1Q 2025). Revenue: kr564.5m (up 14% from 1Q 2025). Net income: kr55.9m (up 11% from 1Q 2025). Profit margin: 9.9% (in line with 1Q 2025). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 17% per year.
Buy Or Sell Opportunity • May 04Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.6% to kr458. The fair value is estimated to be kr598, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 15%.
Price Target Changed • Apr 29Price target increased by 9.1% to kr575Up from kr527, the current price target is an average from 2 analysts. New target price is 20% above last closing price of kr478. Stock is up 9.9% over the past year. The company is forecast to post earnings per share of kr19.24 for next year compared to kr14.67 last year.
New Risk • Apr 10New major risk - Revenue sizeThe company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risk Large one-off items impacting financial results.
공시 • Mar 31MedCap AB (publ), Annual General Meeting, May 04, 2026MedCap AB (publ), Annual General Meeting, May 04, 2026, at 16:00 W. Europe Standard Time. Location: at iva, grev turegatan 16 in stockholm, stockholm Sweden
Recent Insider Transactions • Feb 13Head of Business Area Specialty Pharma recently bought kr780k worth of stockOn the 9th of February, Anders Larnholt bought around 2k shares on-market at roughly kr520 per share. This transaction amounted to 60% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold kr25m more in shares than they bought in the last 12 months.
Reported Earnings • Feb 10Full year 2025 earnings released: EPS: kr14.67 (vs kr14.00 in FY 2024)Full year 2025 results: EPS: kr14.67 (up from kr14.00 in FY 2024). Revenue: kr2.13b (up 18% from FY 2024). Net income: kr219.8m (up 6.0% from FY 2024). Profit margin: 10% (down from 12% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Feb 06MedCap AB (publ) to Report Fiscal Year 2026 Results on Feb 05, 2027MedCap AB (publ) announced that they will report fiscal year 2026 results on Feb 05, 2027
Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. Independent Director Otto Ankarcrona was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
분석 기사 • Jan 30Estimating The Fair Value Of MedCap AB (publ) (STO:MCAP)Key Insights Using the 2 Stage Free Cash Flow to Equity, MedCap fair value estimate is kr577 Current share price of...
Recent Insider Transactions • Dec 08Chairman recently sold kr3.4m worth of stockOn the 5th of December, Karl Tobieson sold around 6k shares on-market at roughly kr537 per share. This transaction amounted to 4.6% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Karl has been a net seller over the last 12 months, reducing personal holdings by kr26m.
분석 기사 • Nov 06Earnings Troubles May Signal Larger Issues for MedCap (STO:MCAP) ShareholdersMedCap AB (publ)'s ( STO:MCAP ) stock showed strength, with investors undeterred by its weak earnings report...
Reported Earnings • Oct 26Third quarter 2025 earnings released: EPS: kr3.42 (vs kr3.57 in 3Q 2024)Third quarter 2025 results: EPS: kr3.42 (down from kr3.57 in 3Q 2024). Revenue: kr504.8m (up 22% from 3Q 2024). Net income: kr51.2m (down 3.2% from 3Q 2024). Profit margin: 10% (down from 13% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Oct 25MedCap AB (publ) to Report Q3, 2026 Results on Oct 23, 2026MedCap AB (publ) announced that they will report Q3, 2026 results on Oct 23, 2026
분석 기사 • Sep 25Is MedCap (STO:MCAP) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • Aug 28A Look At The Intrinsic Value Of MedCap AB (publ) (STO:MCAP)Key Insights The projected fair value for MedCap is kr683 based on 2 Stage Free Cash Flow to Equity MedCap's kr621...
Reported Earnings • Jul 24Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: kr524.1m (up 14% from 2Q 2024). Net income: kr53.7m (down 5.5% from 2Q 2024). Profit margin: 10% (down from 12% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Jul 24+ 2 more updatesMedCap AB (publ) to Report Q1, 2026 Results on Apr 29, 2026MedCap AB (publ) announced that they will report Q1, 2026 results on Apr 29, 2026
Valuation Update With 7 Day Price Move • Jul 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to kr616, the stock trades at a trailing P/E ratio of 45.9x. Average forward P/E is 24x in the Life Sciences industry in Sweden. Total returns to shareholders of 199% over the past three years.
분석 기사 • Jul 13MedCap AB (publ)'s (STO:MCAP) Shares Climb 27% But Its Business Is Yet to Catch UpMedCap AB (publ) ( STO:MCAP ) shares have continued their recent momentum with a 27% gain in the last month alone. The...
공시 • Jun 25MedCap AB (publ) (OM:MCAP) acquired XGX PharmaMedCap AB (publ) (OM:MCAP) agreed to acquire XGX Pharma on June 25, 2025. MedCap AB (publ) (OM:MCAP) completed acquisition of XGX Pharma on June 25, 2025.
Recent Insider Transactions • May 15Chairman recently sold kr22m worth of stockOn the 12th of May, Karl Tobieson sold around 50k shares on-market at roughly kr444 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Karl's only on-market trade for the last 12 months.
공시 • May 10MedCap AB (publ) (OM:MCAP) announces an Equity Buyback for SEK 26 million worth of its shares.MedCap AB (publ) (OM:MCAP) announces a share repurchase program. Under the program, the company will repurchase up to SEK 26 million worth of its shares. The shares shall be acquired at a price per share within the price range applicable on Nasdaq Stockholm at any time, which refers to the interval between the highest bid price and the lowest ask price published continuously by Nasdaq Stockholm. The purpose of the program is to secure the Company's commitment to share-based incentive programs (LTIP 2025/2028) through holdings of unvested shares and to continuously adapt the Company's capital structure to the Company's capital needs and thereby contribute to increased shareholder value, and to enable future acquisitions of companies or businesses to be made through payment with own shares. The program will be valid till August 29, 2025. As of May 7, 2025, the company had 14,981,353 outstanding shares and 0 treasury shares.
분석 기사 • May 07MedCap (STO:MCAP) Strong Profits May Be Masking Some Underlying IssuesMedCap AB (publ) ( STO:MCAP ) just released a solid earnings report, and the stock displayed some strength. Despite...
분석 기사 • May 04Subdued Growth No Barrier To MedCap AB (publ) (STO:MCAP) With Shares Advancing 28%MedCap AB (publ) ( STO:MCAP ) shareholders would be excited to see that the share price has had a great month, posting...
Reported Earnings • Apr 30First quarter 2025 earnings released: EPS: kr3.37 (vs kr3.78 in 1Q 2024)First quarter 2025 results: EPS: kr3.37 (down from kr3.78 in 1Q 2024). Revenue: kr498.3m (up 7.9% from 1Q 2024). Net income: kr50.5m (down 9.8% from 1Q 2024). Profit margin: 10% (down from 12% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • Apr 29Why We Think The CEO Of MedCap AB (publ) (STO:MCAP) May Soon See A Pay RiseKey Insights MedCap to hold its Annual General Meeting on 5th of May Total pay for CEO Anders Dahlberg includes kr3.03m...
Buy Or Sell Opportunity • Apr 19Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.2% to kr386. The fair value is estimated to be kr482, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 30%.
공시 • Apr 03MedCap AB (publ), Annual General Meeting, May 05, 2025MedCap AB (publ), Annual General Meeting, May 05, 2025, at 16:00 W. Europe Standard Time. Location: iva, grev turegatan 16, stockholm Sweden
Buy Or Sell Opportunity • Feb 19Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 27% to kr395. The fair value is estimated to be kr499, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 30%.
Recent Insider Transactions • Feb 14Chief Executive Officer recently bought kr3.9m worth of stockOn the 12th of February, Anders Dahlberg bought around 10k shares on-market at roughly kr391 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Anders has been a buyer over the last 12 months, purchasing a net total of kr4.2m worth in shares.
분석 기사 • Feb 03Some MedCap AB (publ) (STO:MCAP) Shareholders Look For Exit As Shares Take 34% PoundingMedCap AB (publ) ( STO:MCAP ) shareholders that were waiting for something to happen have been dealt a blow with a 34...
공시 • Feb 02MedCap AB (publ) to Report Q3, 2025 Results on Oct 24, 2025MedCap AB (publ) announced that they will report Q3, 2025 results on Oct 24, 2025
Reported Earnings • Feb 01Full year 2024 earnings: EPS in line with expectations, revenues disappointFull year 2024 results: EPS: kr14.00 (up from kr11.63 in FY 2023). Revenue: kr1.84b (up 15% from FY 2023). Net income: kr207.4m (up 20% from FY 2023). Profit margin: 11% (in line with FY 2023). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Jan 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 5.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Buy Or Sell Opportunity • Jan 17Now 33% undervalued after recent price dropOver the last 90 days, the stock has fallen 24% to kr411. The fair value is estimated to be kr609, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 34%. Revenue is forecast to grow by 23% in 2 years. Earnings are forecast to grow by 22% in the next 2 years.
Buy Or Sell Opportunity • Jan 02Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to kr615. The fair value is estimated to be kr501, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 34%.
Buy Or Sell Opportunity • Dec 16Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 22% to kr601. The fair value is estimated to be kr500, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 34%.
Recent Insider Transactions Derivative • Dec 09Chief Executive Officer exercised options and sold kr11m worth of stockOn the 4th of December, Anders Dahlberg exercised 45.00k options at around kr217, then sold 35k of the shares acquired at an average of kr544 per share and kept the remainder. For the year to December 2021, Anders' total compensation was 45% salary and 55% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since December 2023, Anders' direct individual holding has increased from 19.46k shares to 20.00k. Company insiders have collectively sold kr19m more than they bought, via options and on-market transactions in the last 12 months.
분석 기사 • Nov 16We Think MedCap (STO:MCAP) Can Manage Its Debt With EaseLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: kr3.57 (vs kr2.59 in 3Q 2023)Third quarter 2024 results: EPS: kr3.57 (up from kr2.59 in 3Q 2023). Revenue: kr426.0m (up 17% from 3Q 2023). Net income: kr52.9m (up 38% from 3Q 2023). Profit margin: 12% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year whereas the company’s share price has increased by 39% per year.
분석 기사 • Oct 18MedCap AB (publ)'s (STO:MCAP) Earnings Haven't Escaped The Attention Of InvestorsWith a price-to-earnings (or "P/E") ratio of 36x MedCap AB (publ) ( STO:MCAP ) may be sending very bearish signals at...
Recent Insider Transactions • Sep 23Chief Executive Officer recently bought kr265k worth of stockOn the 20th of September, Anders Dahlberg bought around 541 shares on-market at roughly kr491 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Anders' only on-market trade for the last 12 months.
Reported Earnings • Jul 25Second quarter 2024 earnings released: EPS: kr3.84 (vs kr3.16 in 2Q 2023)Second quarter 2024 results: EPS: kr3.84 (up from kr3.16 in 2Q 2023). Revenue: kr469.9m (up 22% from 2Q 2023). Net income: kr56.8m (up 21% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Over the last 3 years on average, earnings per share has increased by 35% per year whereas the company’s share price has increased by 38% per year.
공시 • Jul 25MedCap AB (publ) to Report Q2, 2025 Results on Jul 23, 2025MedCap AB (publ) announced that they will report Q2, 2025 results on Jul 23, 2025
Buy Or Sell Opportunity • Jul 01Now 17% undervaluedOver the last 90 days, the stock has risen 40% to kr523. The fair value is estimated to be kr631, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.
Buy Or Sell Opportunity • Jun 25Now 21% undervaluedOver the last 90 days, the stock has risen 32% to kr500. The fair value is estimated to be kr629, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.
분석 기사 • Jun 06Estimating The Intrinsic Value Of MedCap AB (publ) (STO:MCAP)Key Insights The projected fair value for MedCap is kr631 based on 2 Stage Free Cash Flow to Equity Current share price...
분석 기사 • May 21MedCap AB (publ) (STO:MCAP) Stocks Shoot Up 33% But Its P/E Still Looks ReasonableThe MedCap AB (publ) ( STO:MCAP ) share price has done very well over the last month, posting an excellent gain of 33...
Buy Or Sell Opportunity • May 13Now 21% undervaluedOver the last 90 days, the stock has risen 26% to kr494. The fair value is estimated to be kr626, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.
공시 • May 12MedCap AB (publ) to Report Q1, 2025 Results on Apr 29, 2025MedCap AB (publ) announced that they will report Q1, 2025 results on Apr 29, 2025
분석 기사 • May 04Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Reported Earnings • May 04First quarter 2024 earnings released: EPS: kr3.78 (vs kr1.68 in 1Q 2023)First quarter 2024 results: EPS: kr3.78 (up from kr1.68 in 1Q 2023). Revenue: kr463.1m (up 22% from 1Q 2023). Net income: kr56.0m (up 126% from 1Q 2023). Profit margin: 12% (up from 6.5% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.
공시 • Apr 03MedCap AB (publ), Annual General Meeting, May 06, 2024MedCap AB (publ), Annual General Meeting, May 06, 2024.
공시 • Mar 29MedCap AB (publ) to Report Fiscal Year 2024 Results on Jan 31, 2025MedCap AB (publ) announced that they will report fiscal year 2024 results on Jan 31, 2025
분석 기사 • Feb 15MedCap AB (publ)'s (STO:MCAP) P/E Is Still On The Mark Following 25% Share Price BounceDespite an already strong run, MedCap AB (publ) ( STO:MCAP ) shares have been powering on, with a gain of 25% in the...
Reported Earnings • Feb 02Full year 2023 earnings released: EPS: kr11.63 (vs kr7.94 in FY 2022)Full year 2023 results: EPS: kr11.63 (up from kr7.94 in FY 2022). Revenue: kr1.60b (up 43% from FY 2022). Net income: kr172.2m (up 46% from FY 2022). Profit margin: 11% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improves as stock rises 19%After last week's 19% share price gain to kr380, the stock trades at a trailing P/E ratio of 37.4x. Average trailing P/E is 49x in the Life Sciences industry in Sweden. Total returns to shareholders of 88% over the past three years.
분석 기사 • Dec 21Is Now The Time To Put MedCap (STO:MCAP) On Your Watchlist?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
공시 • Oct 29MedCap AB (publ) to Report Q3, 2024 Results on Oct 25, 2024MedCap AB (publ) announced that they will report Q3, 2024 results on Oct 25, 2024
Reported Earnings • Oct 29Third quarter 2023 earnings released: EPS: kr2.59 (vs kr2.47 in 3Q 2022)Third quarter 2023 results: EPS: kr2.59 (up from kr2.47 in 3Q 2022). Revenue: kr368.2m (up 52% from 3Q 2022). Net income: kr38.3m (up 4.6% from 3Q 2022). Profit margin: 10% (down from 15% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
공시 • Jul 31MedCap AB (publ) to Report First Half, 2024 Results on Jul 19, 2024MedCap AB (publ) announced that they will report first half, 2024 results on Jul 19, 2024
Reported Earnings • Jul 29Second quarter 2023 earnings released: EPS: kr3.16 (vs kr1.42 in 2Q 2022)Second quarter 2023 results: EPS: kr3.16 (up from kr1.42 in 2Q 2022). Revenue: kr390.0m (up 37% from 2Q 2022). Net income: kr46.8m (up 123% from 2Q 2022). Profit margin: 12% (up from 7.4% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year whereas the company’s share price has increased by 27% per year.
공시 • Jul 25MedCap AB (publ) (OM:MCAP) signed an agreement to acquire SurgiCube International B.V. for €8 million.MedCap AB (publ) (OM:MCAP) signed an agreement to acquire Surgicube International B.V. for €8 million on July 24, 2023. Under the transaction, MedCap pays €6 million and adjustments for net debt / cash at closing and an earn-out up to €2 million based on the gross profit growth until December 2024. SurgiCube’s sales in the last 12 months amounted to approximately €3.7 million with almost 24% EBITDA-margin. Key individuals in the business have committed to remain as minority owners, and the former majority owner Ger Vijfvinkel has committed to remain as managing director and then as advisor during a transition phase.
분석 기사 • May 06Do MedCap's (STO:MCAP) Earnings Warrant Your Attention?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
공시 • May 05MedCap AB (publ) to Report Q1, 2024 Results on May 03, 2024MedCap AB (publ) announced that they will report Q1, 2024 results on May 03, 2024
Reported Earnings • May 03First quarter 2023 earnings released: EPS: kr1.68 (vs kr1.32 in 1Q 2022)First quarter 2023 results: EPS: kr1.68 (up from kr1.32 in 1Q 2022). Revenue: kr384.0m (up 46% from 1Q 2022). Net income: kr24.8m (up 27% from 1Q 2022). Profit margin: 6.5% (down from 7.5% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Feb 12Full year 2022 earnings released: EPS: kr7.94 (vs kr6.52 in FY 2021)Full year 2022 results: EPS: kr7.94 (up from kr6.52 in FY 2021). Revenue: kr1.15b (up 24% from FY 2021). Net income: kr117.6m (up 22% from FY 2021). Profit margin: 10% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
분석 기사 • Nov 23These 4 Measures Indicate That MedCap (STO:MCAP) Is Using Debt SafelyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Anders Hansen is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 30Third quarter 2022 earnings released: EPS: kr2.47 (vs kr1.73 in 3Q 2021)Third quarter 2022 results: EPS: kr2.47 (up from kr1.73 in 3Q 2021). Revenue: kr264.0m (up 31% from 3Q 2021). Net income: kr36.6m (up 43% from 3Q 2021). Profit margin: 14% (up from 13% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.
분석 기사 • Sep 21We Ran A Stock Scan For Earnings Growth And MedCap (STO:MCAP) Passed With EaseFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Buying Opportunity • Sep 13Now 21% undervaluedOver the last 90 days, the stock is up 17%. The fair value is estimated to be kr267, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 28%.
Buying Opportunity • Aug 02Now 21% undervaluedOver the last 90 days, the stock is up 36%. The fair value is estimated to be kr273, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 28%.
공시 • Jul 31MedCap AB (publ) to Report Q2, 2023 Results on Jul 28, 2023MedCap AB (publ) announced that they will report Q2, 2023 results on Jul 28, 2023
Board Change • Jul 30High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Anders Hansen is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jun 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Anders Hansen is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공시 • May 12+ 1 more updateMedCap AB (publ) to Report Q1, 2023 Results on May 03, 2023MedCap AB (publ) announced that they will report Q1, 2023 results on May 03, 2023
Reported Earnings • May 06First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2022 results: EPS: kr1.32 (up from kr0.99 in 1Q 2021). Revenue: kr265.8m (up 19% from 1Q 2021). Net income: kr19.6m (up 34% from 1Q 2021). Profit margin: 7.4% (up from 6.6% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.3%. Earnings per share (EPS) exceeded analyst estimates by 13%. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
분석 기사 • Apr 29Does MedCap (STO:MCAP) Deserve A Spot On Your Watchlist?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
공시 • Mar 29MedCap AB (publ) to Report Q4, 2022 Results on Feb 10, 2023MedCap AB (publ) announced that they will report Q4, 2022 results on Feb 10, 2023
Reported Earnings • Feb 11Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: kr6.52 (up from kr4.36 in FY 2020). Revenue: kr939.6m (up 15% from FY 2020). Net income: kr96.5m (up 54% from FY 2020). Profit margin: 10% (up from 7.6% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.3%. Earnings per share (EPS) exceeded analyst estimates by 13%. Over the last 3 years on average, earnings per share has increased by 29% per year and the company’s share price has also increased by 29% per year.
분석 기사 • Feb 01MedCap (STO:MCAP) Seems To Use Debt Rather SparinglyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Valuation Update With 7 Day Price Move • Jan 31Investor sentiment improved over the past weekAfter last week's 18% share price gain to kr162, the stock trades at a trailing P/E ratio of 31.3x. Average trailing P/E is 51x in the Life Sciences industry in Sweden. Total returns to shareholders of 94% over the past three years.
Buying Opportunity • Jan 21Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 24%. The fair value is estimated to be kr184, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.4% per annum over the last 3 years. Earnings per share has grown by 32% per annum over the last 3 years.
Board Change • Jan 02High number of new directorsChairman Karl Tobieson was the last director to join the board, commencing their role in 2021.
Recent Insider Transactions • Dec 30Chief Executive Officer recently bought kr348k worth of stockOn the 27th of December, Anders Dahlberg bought around 2k shares on-market at roughly kr174 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr828k. Anders has been a buyer over the last 12 months, purchasing a net total of kr1.1m worth in shares.
Recent Insider Transactions • Dec 15Investment Manager recently bought kr828k worth of stockOn the 13th of December, Lars Ångman bought around 5k shares on-market at roughly kr166 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.9m more in shares than they have sold in the last 12 months.
Reported Earnings • Oct 30Third quarter 2021 earnings released: EPS kr1.73 (vs kr0.89 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr216.0m (up 23% from 3Q 2020). Net income: kr25.6m (up 95% from 3Q 2020). Profit margin: 12% (up from 7.5% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year whereas the company’s share price has increased by 34% per year.
분석 기사 • Aug 03Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Reported Earnings • Jul 31Second quarter 2021 earnings released: EPS kr1.06 (vs kr1.33 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: kr237.1m (up 13% from 2Q 2020). Net income: kr15.7m (down 18% from 2Q 2020). Profit margin: 6.6% (down from 9.1% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
분석 기사 • May 27Does MedCap (STO:MCAP) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Valuation Update With 7 Day Price Move • May 12Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to kr206, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 40x in the Life Sciences industry in Europe. Total returns to shareholders of 170% over the past three years.
Recent Insider Transactions • May 09Independent Chairman of the Board recently bought kr1.1m worth of stockOn the 7th of May, Peter von Ehrenheim bought around 5k shares on-market at roughly kr220 per share. This was the largest purchase by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months.
분석 기사 • Apr 07Here's Why I Think MedCap (STO:MCAP) Is An Interesting StockSome have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...